

CLAIMS

Sub  
a4  
5 1. A diagnostic agent for leukemia, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

2. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

10 3. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750. S

15 4. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

20 5. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, a single chain antibody and a disulfide stabilized antibody.

25

6. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

SP

Sub  
Q5  
7. A therapeutic agent <sup>a/</sup> for leukemia, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

10

8. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

15

9. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

SP

20

10. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

11. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab',

F(ab')<sub>2</sub>, a single chain antibody and a disulfide stabilized antibody.

12. The therapeutic agent according to claim 7,  
5 wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

10 13. A method for diagnosing leukemia, comprising using an anti-human VEGF receptor Flt-1 antibody.

15 14. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

20 15. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

25 16. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

17. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, a single chain antibody and a disulfide stabilized antibody.

18. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.